share_log

康希諾生物：須予披露的交易 購買結構性存款

CANSINOBIO: DISCLOSEABLE TRANSACTIONPURCHASE OF STRUCTURED DEPOSIT

Hong Kong Stock Exchange ·  May 8 17:45
Summary by Futu AI
康希諾生物於2024年5月8日與渤海銀行簽訂結構性存款協議VI，同意購買本金金額人民幣200百萬元的結構性存款。該結構性存款的期限為2024年5月10日至6月11日，預期年化收益率最高可達2.7%。此次購買結構性存款是使用公司自有資金及先前結構性存款到期贖回款項，並未使用H股首次公開發行募集資金。根據《上市規則》第14.22條的規定，此交易與公司先前的結構性存款協議合併計算後，構成須予披露的交易。康希諾生物表示，此舉旨在提升公司整體資金收益，並認為交易條款公平合理，符合公司及股東利益。
康希諾生物於2024年5月8日與渤海銀行簽訂結構性存款協議VI，同意購買本金金額人民幣200百萬元的結構性存款。該結構性存款的期限為2024年5月10日至6月11日，預期年化收益率最高可達2.7%。此次購買結構性存款是使用公司自有資金及先前結構性存款到期贖回款項，並未使用H股首次公開發行募集資金。根據《上市規則》第14.22條的規定，此交易與公司先前的結構性存款協議合併計算後，構成須予披露的交易。康希諾生物表示，此舉旨在提升公司整體資金收益，並認為交易條款公平合理，符合公司及股東利益。
On 8 May 2024, Conshino Bio signed Structured Deposit Agreement VI with Bohai Bank, agreeing to purchase RMB200 million of structured deposits in the amount of this amount. The structured deposit has a maturity of 10 May to 11 June 2024, with an annualized yield of up to 2.7%. THIS PURCHASE OF STRUCTURED DEPOSITS WAS REDEEMED USING THE COMPANY'S OWN FUNDS AND MATURITIES OF PREVIOUS STRUCTURED DEPOSITS AND DID NOT USE THE INITIAL PUBLIC OFFERING OF H SHARES TO RAISE FUNDS. Pursuant to Section 14.22 of the Listing Rules, this transaction constitutes a disclosable transaction when calculated in conjunction with the Company's previous structured deposit agreement. Consino Bio stated that the move is aimed at enhancing the company's overall return on capital and believes that the terms of the transaction are fair and reasonable and in the best interests of the company and its shareholders.
On 8 May 2024, Conshino Bio signed Structured Deposit Agreement VI with Bohai Bank, agreeing to purchase RMB200 million of structured deposits in the amount of this amount. The structured deposit has a maturity of 10 May to 11 June 2024, with an annualized yield of up to 2.7%. THIS PURCHASE OF STRUCTURED DEPOSITS WAS REDEEMED USING THE COMPANY'S OWN FUNDS AND MATURITIES OF PREVIOUS STRUCTURED DEPOSITS AND DID NOT USE THE INITIAL PUBLIC OFFERING OF H SHARES TO RAISE FUNDS. Pursuant to Section 14.22 of the Listing Rules, this transaction constitutes a disclosable transaction when calculated in conjunction with the Company's previous structured deposit agreement. Consino Bio stated that the move is aimed at enhancing the company's overall return on capital and believes that the terms of the transaction are fair and reasonable and in the best interests of the company and its shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.